SuperworthAligos Therapeutics EPS ALGS
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$7.30
- Latest quarter, Q2 FY26
- −$0.14
- Fiscal year 2025
- −$8.59
Aligos Therapeutics' earnings per share was −$7.30 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.14.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$8.59 | n/a |
| FY2024 | −$20.92 | n/a |
| FY2023 | −$39.90 | n/a |
| FY2022 | −$56.50 | n/a |
| FY2021 | −$80.25 | n/a |
| FY2019 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.14 | n/a | −$7.30 | |
| Q1 FY26 | −$2.21 | n/a | −$8.69 | |
| Q4 FY25 | −$1.91 | n/a | −$8.59 | |
| Q3 FY25 | −$3.04 | n/a | −$19.76 | |
| Q2 FY25 | −$1.53 | −289% | −$19.79 | |
| Q1 FY25 | −$2.11 | n/a | −$17.45 | |
| Q4 FY24 | −$13.08 | n/a | −$20.92 | |
| Q3 FY24 | −$3.07 | n/a | −$13.37 | |
| Q2 FY24 | $0.81 | n/a | −$20.67 | |
| Q1 FY24 | −$5.58 | n/a | −$32.23 | |
| Q4 FY23 | −$5.53 | n/a | −$39.90 | |
| Q3 FY23 | −$10.37 | n/a | −$47.12 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Aligos Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.